Skip to main content
. Author manuscript; available in PMC: 2013 Mar 15.
Published in final edited form as: Clin Cancer Res. 2012 Jan 30;18(6):1655–1662. doi: 10.1158/1078-0432.CCR-11-2890

Figure 6. Effects of veliparib, olaparib and iniparib on pADPr synthesis.

Figure 6

A, following a 4-h treatment with the indicated agent, SKOV3 cells were treated with MMS in the continued presence of the small molecule inhibitor, fixed, stained for pADPr and examined by confocal microscopy. B, mean fluorescence of pADPr in nuclei after treatment of cells with diluent (open bar) or 1 mM MMS (closed bars) in the presence of diluent or the indicated agent at 1, 10 and 100 µM. Error bars, ± SEM for 30 nuclei.